AG
REGN icon

Aperio Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Aperio Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$33.4M Sell
69,153
-10,183
-13% -$5.5M 0.1% 199
2020
Q3 		$44.4M Buy
79,336
+7,136
+10% +$4.33M 0.15% 131
2020
Q2 		$45M Buy
72,200
+17,805
+33% +$10.1M 0.17% 116
2020
Q1 		$26.6M Buy
54,395
+23,864
+78% +$9.84M 0.12% 179
2019
Q4 		$11.5M Buy
30,531
+7,355
+32% +$2.47M 0.04% 460
2019
Q3 		$6.43M Sell
23,176
-3,623
-14% -$1.07M 0.03% 623
2019
Q2 		$8.39M Sell
26,799
-13,571
-34% -$4.52M 0.03% 530
2019
Q1 		$16.6M Buy
40,370
+2,940
+8% +$1.21M 0.07% 308
2018
Q4 		$14M Buy
37,430
+5,038
+16% +$1.84M 0.07% 307
2018
Q3 		$13.1M Buy
32,392
+4,060
+14% +$1.55M 0.06% 360
2018
Q2 		$9.78M Buy
28,332
+2,045
+8% +$640K 0.05% 444
2018
Q1 		$9.05M Buy
26,287
+1,330
+5% +$463K 0.05% 451
2017
Q4 		$9.38M Sell
24,957
-1,301
-5% -$527K 0.05% 435
2017
Q3 		$11.7M Sell
26,258
-806
-3% -$384K 0.07% 348
2017
Q2 		$13.3M Buy
27,064
+7,649
+39% +$3.35M 0.08% 296
2017
Q1 		$7.52M Sell
19,415
-2,375
-11% -$880K 0.05% 418
2016
Q4 		$8M Sell
21,790
-3,389
-13% -$1.29M 0.06% 367
2016
Q3 		$10.1M Buy
25,179
+1,566
+7% +$628K 0.07% 317
2016
Q2 		$8.25M Buy
23,613
+2,414
+11% +$930K 0.06% 341
2016
Q1 		$7.64M Sell
21,199
-2,270
-10% -$935K 0.07% 343
2015
Q4 		$12.7M Buy
23,469
+3,217
+16% +$1.74M 0.12% 198
2015
Q3 		$9.42M Buy
20,252
+2,710
+15% +$1.46M 0.1% 251
2015
Q2 		$8.95M Buy
17,542
+2,549
+17% +$1.24M 0.09% 263
2015
Q1 		$6.77M Buy
14,993
+2,241
+18% +$950K 0.08% 323
2014
Q4 		$5.23M Buy
12,752
+1,078
+9% +$424K 0.06% 368
2014
Q3 		$4.21M Buy
11,674
+1,546
+15% +$518K 0.06% 395
2014
Q2 		$2.86M Buy
10,128
+1,202
+13% +$356K 0.04% 492
2014
Q1 		$2.68M Buy
+8,926
New +$2.75M 0.04% 603
2013
Q4 		– Sell
-6,234
Closed -$1.79M – 670
2013
Q3 		$1.95M Buy
6,234
+115
+2% +$30.2K 0.04% 597
2013
Q2 		$1.38M Buy
+6,119
New +$1.42M 0.03% 634

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Aperio Group's REGN Position: Q4 2020 in Review

Aperio Group reduced its Regeneron Pharmaceuticals (REGN) stake by 13% in Q4 2020, selling an estimated $5.5M and leaving 69,153 shares worth $33.4M. The position accounts for 0.1% of the portfolio, ranked #199.

Aperio Group first reported a position in REGN in Q2 2013 and has held it in 30 quarters since. The position peaked at $45M in Q2 2020. 904 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

  • Aperio Group held 69,153 shares of Regeneron Pharmaceuticals worth $33.4M as of Q4 2020.
  • Aperio Group sold 10,183 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $5.5M.
  • Regeneron Pharmaceuticals made up 0.1% of Aperio Group's portfolio in Q4 2020, its #199 holding.
  • Aperio Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 30 quarters since.
  • Aperio Group's Regeneron Pharmaceuticals position peaked at $45M in Q2 2020.
  • 904 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.